Targeting HER2 alterations in non-small cell lung cancer: therapeutic breakthrough and challenges

Non-small cell lung cancer (NSCLC) is a heterogeneous disease characterized by a broad spectrum of oncogenic driver alterations. Currently, targeted therapies are the standard treatment for most oncogene-driven patients [1]. However, not all oncogenic drivers, such as human epidermal growth factor receptor 2 (HER2), have approved targeted agents.
Source: Cancer Treatment Reviews - Category: Cancer & Oncology Authors: Tags: Anti-tumour Treatment Source Type: research